u/peptidemeter_pat

Substantial weight loss independently moves lipids, liver enzymes and several other markers. Attributing a change to a compound while losing weight is confounded by design.

ApoB counts atherogenic particles rather than the cholesterol they carry, which is why it can diverge from LDL-C and why it is the addition most worth making.

jurisdiction first, everything else is downstream

the Medsafe position in New Zealand is its own thing entirely

The PeptideMeter one was mine. 99.2%, batch SSA-2507, different quarter entirely.

What makes this set unusual is the inter-service agreement. Three labs on three batches within 0.2 of each other is tighter than I would expect from variance alone, which is either a very consistent process or a very lucky run of three. Ask me again at six.

cost and supply are the two most common reasons and both are legitimate

lina_adebayo is right that regain is a documented outcome rather than a character verdict.

i have tried putting n next to every average and people still compare the averages.

This is the first paired run anybody has posted and I will run a second next month on a different compound.

The thing to keep in mind while reading it: "same nominal batch" is doing a lot of work. Ask which stock you are being sent and ask for the lot-specific document for that stock — they answer both, and it turns a nominal batch into an actual one.

trying that formatting next update. if it changes how people quote it i will report back.

alright. range first, mean second, n in brackets. changing the template.

which is why vendor-level averages should always ship with a range. i publish both and people quote the average anyway.

PeptideMeter, Medutest and VendorInvestigate have all verified them at some point, which is three of four services and more than most. that is context, not exoneration.

this is exactly why i publish ranges, and exactly why people quote the averages anyway. i am considering leading with the range next update just to see what happens.

one result is a data point, agreement between two services is evidence

Hair shedding after significant weight loss is a telogen effect that follows the rate of loss. It is not specific to these compounds and it resolves.

Nudging rather than removing: the standard template is in the sidebar and this post is missing the batch field.

Withdrawal studies across this class consistently show substantial regain after discontinuation, with appetite typically returning before weight changes. That is a description of the pharmacology of a chronic condition.

I would not post that as a finding. It is a single result and the template asks you to say so.

What documentation accompanied the shipment?

split a vial across two services once and you will never argue about ground truth again

the answer for Spain does not apply anywhere else

Merged with the other thread on the same batch so the results sit together.

A series across separate lots estimates a process. Repeat tests on one lot estimate the measurement. Both are useful and they answer different questions.

Constipation is mostly reduced intake plus reduced fluid, not a direct effect. That is why the boring fibre and water answer keeps working.

a single ALT outside range is a reason to repeat, not to panic

Adding the obvious one — take it to whoever ordered the panel. This board cannot read it for you.

Substantial weight loss independently moves lipids, liver enzymes and several other markers. Attributing a change to a compound while losing weight is confounded by design.

Nudging rather than removing: the standard template is in the sidebar and this post is missing the batch field.

The confounding problem, stated plainly, because this board keeps stepping on it.

Substantial weight loss moves lipids, liver enzymes, insulin sensitivity markers and several others in its own right. If you are losing weight while taking something, any change in those markers has at least two candidate explanations and you cannot separate them from your own panel.

What you can do is standardise, take a baseline, keep the series long, and be honest in your posts about what is and is not attributable. The threads that say "this compound did X to my fasting insulin" almost never have the design to support the claim, mine included.

Not convinced by that mechanism. Slowed gastric emptying explains fullness and reflux; it does not explain what you are describing.

Not convinced by that mechanism. Slowed gastric emptying explains fullness and reflux; it does not explain what you are describing.

baseline before you start is worth more than any later panel

Posted a question here with my address in the screenshot. A mod removed it within minutes, which I appreciated.

Small fix — the shedding follows the rate of weight loss, not the compound, and it is temporary.

assay method matters, especially between different labs

Nudging rather than removing: the standard template is in the sidebar and this post is missing the batch field.

Retitled — the original stated a discrepancy the numbers do not show.

vendor, compound, batch, service, result — that is the template

That service reports area percent by default. Worth stating, since the thread has been comparing it to a mass figure.

Merged with the other thread on the same batch so the results sit together.

Agreed — the template exists because a result without the batch and the claim is unanchored.